Pharmacokinetics of Orally Administered GS-441524 in Dogs

Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury(®)) remains contentious. We previously pointed out pharmacokinetic, pharmacodynamic and toxicology reasons for why its parent nucleoside GS-441524, is better suited for COVID-19 treatment. Here, we assess the oral...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:bioRxiv
Autores principales: Yan, Victoria C., Pham, Cong-Dat, Yan, Matthew J., Yan, Alexander J., Khadka, Sunada, Arthur, Kenisha, Ackroyd, Jeffrey J., Georgiou, Dimitra K., Roon, Laura E., Bushman, Lane R., Anderson, Peter L., Li, Chun, Muller, Florian L.
Formato: Artigo
Lenguaje:Inglês
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183013/
https://ncbi.nlm.nih.gov/pubmed/34100016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.02.04.429674
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares